ImpriMed

ImpriMed is transforming both veterinary and human oncology with its cutting-edge AI-driven precision medicine approach. ImpriMed's innovative AI models leverage live cancer cell analytics to enable oncologists to make precise, data-driven treatment decisions tailored to individual patients. With proven success in over 10,000 cases in dogs and cats, the company is now expanding into human cancer treatment. Additionally, the live-cell-based drug efficacy assessment platform offers pharmaceutical companies an invaluable tool to pretest drug compounds on their target patients' live cells, enhancing clinical trial success rates and streamlining market entry.